H-89, CAS 127243-85-0

Product Description: H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.

Applications: Neuroscience-Neuromodulation

Formula: C20H20BrN3O2S

Citations: Acta Biochim Biophys Sin (Shanghai). 2023 Nov 15;55(12):1855-1863./Am J Physiol Cell Physiol. 2024 Apr 22./Anim Nutr. 2022./Aquac Rep. 2024 Jun, 36, 102110./Aquac Res. 2020;00:1-10./Arch Biochem Biophys. 2020 Jul 15;687:108375./Biomaterials. 2022: 121902/Biomed Pharmacother. 2022 Feb 24;148:112728./BMC Biol. 2024 May 3;22(1):104./BMC Genomics. 2024 Apr 3;25(1):337./BMC Pharmacol Toxicol. 2023 Nov 20;24(1):63./Bone. 2020 Jun;135:115326./Brain Behav Immun. 2023 Nov 19:115:667-679./Brain Behav Immun. 2024 Mar 29:119:36-50./Cancer Cell Int. 2019 Sep 23;19:241./Cell Commun Signal. 2021 Oct 11;19(1):103./Cell Metab. 2021 Mar 2;33(3):565-580.e7./Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2./Cell Mol Immunol. 2023 Jan 5./Cell Rep. 2021 Sep 21;36(12):109726./Cell Rep. 2022 Oct 18;41(3):111498./Cells. 2023 Apr 6, 12(7), 1098./Clin Transl Med. 2021 Jan 1./CNS Neurosci Ther. 2024 May;30(5):e14742./Ecotoxicol Environ Saf. 2021 Feb 25;214:112005./Endocrinology. 2023 Mar 17;bqad042./Evid-Based Compl Alt. Dec 12./Fitoterapia. 2022 Oct 15;105336./Front Oncol. 2021 Oct 6;11:738300./Front Physiol. 05 January 2022./Front Physiol. 2021 Oct 28;12:770430./Genes Dis. 2020 Nov 21;8(6):867-881./Heart Surg Forum. 2024 Mar 17./Infect Immun. 2018 Dec 19;87(1). pii: e00508-1/Int J Mol Sci. 2018 Oct 7;19(10). pii: E3053. /Int J Mol Sci. 2022, 23(20), 12595./Int J Mol Sci. 2023 Jan 16;24(2):1771./Int J Mol Sci. 2023, 24(1), 320./iScience. 2021, 102820./J Agric Food Chem. 2023 Oct 23./J Biol Chem. 2021 Apr 8;100644./J Bone Miner Metab. 2021 Apr 8./J Cell Mol Med. 2024 Apr;28(8):e18303./J Exp Clin Cancer Res. 2021 Apr 8;40(1):122./J Exp Clin Cancer Res. 2024 Apr 4;43(1):105./J Int Med Res. 2021 Mar;49(3):300060521999527./J Integr Agric. 2023 Feb 24./J Mater Sci Technol. 2023 Jun 30./J Neurophysiol. 2023 Dec 5./J Neurosci. 2016 Oct 12;36(41):10560-10573./J Orthop Surg Res. 2023 Nov 8;18(1):849./J Periodontol. 2019 Sep;90(9):1002-1013./Korean J Pain. 2023 Jul 1;36(3):335-346./Microbiol Res. 2024 May 24:285:127779./Mol Brain. 2021 Jul 19;14(1):116./Mol Cell. 2023 Feb 22;S1097-2765(23)00102-8./Mol Reprod Dev. 2022 Apr 26./Nat Commun. 2022 Nov 4;13(1):6648./Neuro Oncol. 2024 Jan 5;26(1):137-152./Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528./NPJ Biofilms Microbiomes. 2023 Feb 8;9(1):8./Nutrients. 2020 Jan 26;12(2):329./Proteome Sci. 2023 Oct 11;21(1):16./Psychoneuroendocrinology. 2020 Jul;117:104680./Res Sq. 2024 May 23./Research Square Preprint. 2020 Oct./Research Square Preprint. 2023 Sep 13./Royal Society of Chemistry. 2020, 11, 1132-1139./Sci Signal. 2020 Nov 24;13(659):eaax0273./Signal Transduct Target Ther. 2023 Aug 9;8(1):290./Stem Cell Res Ther. 2020 Jan 3;11(1):2./Theranostics. 2021 Mar 24;11(12):5650-5674./Toxicol Lett. 2022 Feb 7;359:84-95./Acta Pharm Sin B. 2023 Dec 16./Adv Sci (Weinh). 2021 Oct 31;e2100808./Aging (Albany NY). 2018 Jul 24;10(7):1722-1744. /Aging (Albany NY). 2020 Jun 9;12(11):10951-10968./Aging Cell. 2018 Jun;17(3):e12754. /Biochem Biophys Res Commun. 2024 Feb 15, 149689./Biol Trace Elem Res. 2020 Sep 14. /bioRxiv. 2024 Feb 8./Cell Commun Signal. 2022 Apr 12;20(1):52./Elife. 2023 Jan 16;12:e81438./Exp Cell Res. 2021 Feb 15;399(2):112482./Exp Ther Med. January 31, 2022./FASEB J. 2020 Oct;34(10):13376-13395./Front Pharmacol. 2018 Apr 12;9:362. /Harvard Medical School LINCS LIBRARY/IJMPNP. 2019,5(1): 8-15./Int Immunopharmacol. 2024 Jan 12:128:111490./Int J Biol Sci. 2023 Apr 2,19./J Bone Miner Res. 2021 May 5./J Cell Mol Med. 2020 Apr;24(8):4736-4747./J Funct Foods. 2023 Dec, 111, 105902./Life Sci. 2022 May 28;120676./Nat Commun. 2023 May 31;14(1):3159./Nat Metab. 2024 Mar 18./PeerJ. October 25, 2022./Peptides. 2022 Jun 2;170824./Phytother Res. 2022 Nov 25./Prog Neurobiol. 2021 Mar 22;102041./Purinergic Signal. 2022 Jul 2./Reprod Sci. 2022 Oct 7./Sci Total Environ. 2022 Oct 10;842:156854./Stem Cell Res Ther. 2020 May 19;11(1):182./Theranostics. 2021 Jan 1;11(6):2612-2633./Vet Microbiol. 2021, 109061.

References: [1]Chijiwa T, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267-72./[2]Blazev R, et al. Effects of the PKA inhibitor H-89 on excitation-contraction coupling in skinned and intact skeletal muscle fibres. J Muscle Res Cell Motil. 2001;22(3):277-86./[3]Hosseini-Zare MS, et al. Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice. Eur J Pharmacol. 2011 Nov 30;670(2-3):464-70.

CAS Number: 127243-85-0

Molecular Weight: 446.36

Compound Purity: 99.64

Research Area: Neurological Disease

Solubility: DMSO : 100 mg/mL (ultrasonic)

Target: Autophagy;PKA

• Artikelnummer: MEXHY-15979-10.1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-15979-10.1
• Green Labware: Nein
• Verpackungseinheit: 10mM/1mL
• Mengeneinheit: STK